Gannet BioChem
Chris Edwards is an accomplished finance executive with extensive experience in leading financial operations across various sectors. Currently serving as Chief Financial Officer at Gannet BioChem since February 2025, Chris previously held the same role at SOLESIS, managing finance activities and driving growth strategies for the company and its subsidiaries. Prior to SOLESIS, Chris worked at inVentiv Health as Vice President of Shared Services, implementing global service models and enhancing operational efficiency. Key roles at ConvaTec and Bristol-Myers Squibb included transforming finance organizations, overseeing large teams, and supporting significant business growth initiatives. Chris holds an MBA in Accounting and Finance from The University of Manchester and is a member of the Chartered Institute of Management Accountants, having earned a CIMA designation.
This person is not in any teams
This person is not in any offices
Gannet BioChem
With over 30 years of expertise, Gannet BioChem is a leading specialty CDMO specializing in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents—essential components in advanced biopharmaceutical and therapeutic products. Operating from a state-of-the-art 124,000 sq. ft. FDA-inspected facility in Huntsville, Alabama, Gannet BioChem delivers end-to-end GMP production, supporting clinical and commercial therapeutics. With a highly experienced team, flexible production capabilities, and a commitment to quality, Gannet BioChem provides reliable, innovative solutions to meet the evolving needs of the global biopharmaceutical industry.